PHARVARIS N.V. EO -12 (9EN) - Total Assets
Based on the latest financial reports, PHARVARIS N.V. EO -12 (9EN) holds total assets worth €301.45 Million EUR (≈ $352.43 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PHARVARIS N.V. EO -12 - Total Assets Trend (2021–2025)
This chart illustrates how PHARVARIS N.V. EO -12's total assets have evolved over time, based on quarterly financial data. Also see 9EN market cap overview for the company's overall valuation and market capitalisation.
PHARVARIS N.V. EO -12 - Asset Composition Analysis
Current Asset Composition (December 2025)
PHARVARIS N.V. EO -12's total assets of €301.45 Million consist of 99.2% current assets and 0.8% non-current assets. Review PHARVARIS N.V. EO -12 (9EN) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 96.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how PHARVARIS N.V. EO -12's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for PHARVARIS N.V. EO -12 for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PHARVARIS N.V. EO -12's current assets represent 99.2% of total assets in 2025, a decrease from 99.8% in 2021.
- Cash Position: Cash and equivalents constituted 96.8% of total assets in 2025, down from 98.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
PHARVARIS N.V. EO -12 Competitors by Total Assets
Key competitors of PHARVARIS N.V. EO -12 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
PHARVARIS N.V. EO -12 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.11 | 12.60 | 19.08 |
| Quick Ratio | 10.11 | 12.60 | 19.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €269.56 Million | €266.44 Million | €295.91 Million |
PHARVARIS N.V. EO -12 - Advanced Valuation Insights
This section examines the relationship between PHARVARIS N.V. EO -12's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.15 |
| Latest Market Cap to Assets Ratio | 5.53 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | €301.45 Million |
| Market Capitalization | $1.67 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values PHARVARIS N.V. EO -12's assets at a significant premium (5.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: PHARVARIS N.V. EO -12's assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for PHARVARIS N.V. EO -12 (2021–2025)
The table below shows the annual total assets of PHARVARIS N.V. EO -12 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €301.45 Million ≈ $352.43 Million |
+3.46% |
| 2024-12-31 | €291.37 Million ≈ $340.65 Million |
-26.92% |
| 2023-12-31 | €398.69 Million ≈ $466.12 Million |
+137.70% |
| 2022-12-31 | €167.73 Million ≈ $196.10 Million |
-20.91% |
| 2021-12-31 | €212.09 Million ≈ $247.96 Million |
-- |
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more